Q1 2022 13F Holders as of 31 Mar 2022
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
100,410,416
-
Share change
-
-42,495,983
-
Total reported value
-
$65,716,457
-
Put/Call ratio
-
1.9%
-
Price per share
-
$0.65
-
Number of holders
-
134
-
Value change
-
-$29,271,843
-
Number of buys
-
43
-
Number of sells
-
69
Institutional Holders of ZIOPHARM ONCOLOGY INC - COM (TCRT) as of Q1 2022
As of 31 Mar 2022,
ZIOPHARM ONCOLOGY INC - COM (TCRT) was held by
134 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
100,410,416 shares.
The largest 10 holders included
BlackRock Inc., MSD Partners, L.P., DISCOVERY CAPITAL MANAGEMENT, LLC / CT, VANGUARD GROUP INC, STATE STREET CORP, GOLDMAN SACHS GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, JPMORGAN CHASE & CO, Nuveen Asset Management, LLC, and TWO SIGMA ADVISERS, LP.
This page lists
134
institutional shareholders reporting positions in this security
for the Q1 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.